Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1096 How Manage Multiple Small Bowel Neuroendocrine Tumors?

Introduction: Multiple small bowel neuroendocrine tumors (SB-NET) represent 30% of SB-NET.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Pasquet A

Authors: Pasquer A, Walter T, Hervieu V, Forestier J, Scoazec J,

Keywords: small bowel, surgery, prognosis, multiple,

#1081 High Thyrocalcitonin Serum Level in Neuroendocrine Tumors: Characteristics, Prognosis and Interest in Follow-Up?

Introduction: Thyrocalcitonin (TCT) is usually associated with medullary thyroid cancer. However, some neuroendocrine tumors (NETs) have also high serum TCT levels.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Nozière C, Chardon L, Lombard-Bohas C, Goichot B, Hervieu V,

Keywords: thyrocalcitonin,

#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?

Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Dussol A, Joly M, Hervieu V, Forestier J, Lombard-Bohas C,

Keywords: gemox, alkylating agent, MGMT,

#1032 Clinico-Biological and Histological Predictive Factors and Markers of Response to Everolimus in Neuroendocrine Tumors

Introduction: Several systemic treatments are available for metastatic neuroendocrine Tumors (NETs), including everolimus, but there is no predictive factor of response to these treatments.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Walter T

Authors: Benslama N, Bollard J, Vercherat C, Roche C, Hervieu V,

Keywords: neuroendocrine tumors, everolimus, markers, p-p70S6K,

#748 O6-Methylguanine-DNA Methyltransferase Deficiency in Neuroendocrine Tumors and Correlation with Response to Alkylating Agents (Temozolomide, Streptozotocin, Dacarbazine)

Introduction: Low O6-methylguanine-DNA methyltransferase (MGMT) expression is predictive of response to alkylants in some tumor types.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Van Brakel B, Walter T, Hervieu V, Forestier J, Chayvialle J,

Keywords: MGMT,